CaDAnCe-101 (BGB-16673)

A Phase 1, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Patients With B-Cell Malignancies

Arms / Cohorts

Experimental: Dose Finding:Part 1a: BGB-16673

Accepting patients

Experimental:Part 1b: BGB-16673

Accepting patients

Experimental:Part 1c: BGB-16673

Accepting patients

Experimental:Part 1d: BGB-16673

Accepting patients

Experimental:Part 1f: BGB-16673

Accepting patients

Experimental: Dose Expansion:Part 2: BGB-16673

Not yet accepting

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 828-2206

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.